ORANGE COUNTY, Fla. – A wide variety of elections took place in Orange County on Tuesday, March 10. Residents from Apopka to Winter Park casted ballots on commissioner, mayoral and council seat ...

Good day, and welcome to the Tango Therapeutics conference call. [Operator Instructions] Please note, this call is being recorded. I'd now like to turn the call over to Liz Hickin, Vice President, ...

A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to ...

Tri-complex inhibitors (TCIs) are molecular glues that bind to active GTP-bound RAS and recruit the intracellular chaperone cyclophilin A (CYPA) to generate a synthetic inhibitory complex that blocks ...

Dean Fioresi is a web producer for CBS Los Angeles. He covers breaking news throughout Southern California. When he's not writing about local events, he enjoys focusing on sports and entertainment.

Primary contests will be held in six states on Tuesday. We’ll be paying close attention to California, where dozens of candidates are vying to replace Gov. Gavin Newsom in an open primary. Here’s what ...

In her new memoir, “View From the East Wing,” former first lady Jill Biden offers a detailed accounting of her husband’s presidency. The book unfolds in two parts: First, the joys and challenges of ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

Dana-Farber investigators and colleagues across the country report from a clinical trial of a RAS(ON) multi-selective inhibitor in pancreatic cancer, given as a daily pill, showing that the drug is ...